FindTrial
Sign In

Pharmacodynamic study of Morphine and Tapentadol in Palliative Oncology

Population Pharmacodynamic Model of Morphine and Tapentadol in Palliative Oncology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/01/023083
Enrollment
300
Registered
2020-01-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G319- Degenerative disease of nervous system, unspecified

Interventions

None listed

Sponsors

Manipal Academy of Higher Education
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients above 18 years of age visiting the palliative care department having the prescription of Morphine in either of the dosage form or oral Tapentadol for pain management with the diagnosis of cancer of any type.

Exclusion criteria

Exclusion criteria: Incomplete case records, Patients who missed a follow-up

Design outcomes

Primary

MeasureTime frame
Pain scale will be measured using Edmonton Symptom Assessment Scale at various time intervals after the administration of intervention. The optimized dose will be estimated using population pharmacodynamic approach.Timepoint: Pain scale will be measured using Edmonton Symptom Assessment Scale at various time intervals after the administration of intervention. The optimized dose will be estimated using population pharmacodynamic approach.—

Secondary

MeasureTime frame
To identify the impact of covariates in the pharmacodynamic model of tapentadol and morphineTimepoint: End of the study—

Countries

India

Contacts

Public ContactElstin Anbu Raj S

Manipal Academy of Higher Education

msv.rajan@manipal.edu9886921414

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026